Amarin gets boost from the American Diabetes Association
Vascepa, the fish oil-derived heart drug sold by Amarin, will now be recommended in treatment guidelines released by the American Diabetes Association. The drug should be considered for some patients with diabetes who are at high risk of a heart attack or stroke and have elevated levels of triglycerides, or particles of fat in the blood, the guidelines now say, based on the results of the large study, REDUCE-IT, that was published in the New England Journal of Medicine last fall.
How much does the ADA’s recommendation matter?
“I believe it does matter, especially after Amarin gets the expanded indication,” said Michael Davidson, a professor and director of the lipid clinic at the University of Chicago Pritzker School of Medicine. Davidson co-founded an Amarin rival that was purchased by AstraZeneca; he would be entitled to payments from that deal if that drug met certain timelines, but he said it is now virtually impossible for that to happen.
He pointed out that Amarin will be able to reference the ADA guidelines in promotional and continuing medical education trials. Still, he said, use of Vascepa is likely ramp up slowly, and the drug “could take years to reach its full potential.”
How much does the ADA’s recommendation matter?
“I believe it does matter, especially after Amarin gets the expanded indication,” said Michael Davidson, a professor and director of the lipid clinic at the University of Chicago Pritzker School of Medicine. Davidson co-founded an Amarin rival that was purchased by AstraZeneca; he would be entitled to payments from that deal if that drug met certain timelines, but he said it is now virtually impossible for that to happen.
He pointed out that Amarin will be able to reference the ADA guidelines in promotional and continuing medical education trials. Still, he said, use of Vascepa is likely ramp up slowly, and the drug “could take years to reach its full potential.”
No hay comentarios:
Publicar un comentario